计算溶液所需的质量、体积或浓度。
Rilematovir (JNJ-678) 是一种融合蛋白抑制剂,具有抗病毒活性和低细胞毒性。 Rilematovir 可用于呼吸道合胞病毒治疗的研究。
Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research.
In Vitro
Rilematovir is a small-molecule respiratory syncytial virus (RSV) fusion inhibitor currently under clinical evaluation in infants hospitalized for RSV infection. Rilematovir binds to RSV F protein in its prefusion conformation. Rilematovir displays very potent antiviral activity and low cytotoxicity. In addition to its activity against the RSV A2 strain, Rilematovir is also highly active against a number of RSV strains from both A and B subtypes. The EC 50 in an RSV infection assay using HeLa cells is 460 pM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Oral treatment of neonatal lambs with Rilematovir, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
IC50& Target:Fusion protein
| ALogP | 2.9 |
|---|